Zevra Therapeutics, Inc. ZVRA Cash and cash equivalents, end of period
Cash and cash equivalents, end of period at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.
The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zevra Therapeutics, Inc.'s cash and cash equivalents, end of period.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zevra Therapeutics, Inc.'s cash and cash equivalents, end of period?
- Zevra Therapeutics, Inc. (ZVRA) reported cash and cash equivalents, end of period of $95.6M in Q1 2026.
- How has Zevra Therapeutics, Inc.'s cash and cash equivalents, end of period changed year-over-year?
- Zevra Therapeutics, Inc.'s cash and cash equivalents, end of period increased by 156.0% year-over-year, from $37.34M to $95.6M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s cash and cash equivalents, end of period?
- Over 2 years (2023 to 2025), Zevra Therapeutics, Inc.'s cash and cash equivalents, end of period has grown at a 20.4% compound annual growth rate (CAGR), from $43.05M to $62.41M.